Literature DB >> 8647259

Cell surface binding and activation of gelatinase A induced by expression of membrane-type-1-matrix metalloproteinase (MT1-MMP).

H Sato1, T Takino, T Kinoshita, K Imai, Y Okada, W G Stetler Stevenson, M Seiki.   

Abstract

Gelatinase A is secreted as a proenzyme (progelatinase A) which is activated and bound on the surface of tumor and normal cells. We have reported that the expression of a membrane-type-1-matrix metalloproteinase (MT1-MMP) induces activation of progelatinase A. Here we demonstrate that the expression of MT1-MMP in COS-1 cells induces cell-surface binding of progelatinase A which is consequently processed to an intermediate form. Processing from the intermediate to the fully active form is dependent on the gelatinase A concentration. These results suggest that the cell-surface binding concentrates the gelatinase A intermediate form locally to allow autoproteolytic processing to the fully active form.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8647259     DOI: 10.1016/0014-5793(96)00389-4

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  39 in total

1.  Transmembrane/cytoplasmic domain-mediated membrane type 1-matrix metalloprotease docking to invadopodia is required for cell invasion.

Authors:  H Nakahara; L Howard; E W Thompson; H Sato; M Seiki; Y Yeh; W T Chen
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

Review 2.  Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.

Authors:  Xi Wang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2017-09-19

3.  Activation of proMMP-2 by U46619 occurs via involvement of p(38)MAPK-NFκB-MT1MMP signaling pathway in pulmonary artery smooth muscle cells.

Authors:  Animesh Chowdhury; Soumitra Roy; Tapati Chakraborti; Kuntal Dey; Sajal Chakraborti
Journal:  Mol Cell Biochem       Date:  2013-09-25       Impact factor: 3.396

Review 4.  Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression.

Authors:  Kyle J Isaacson; M Martin Jensen; Nithya B Subrahmanyam; Hamidreza Ghandehari
Journal:  J Control Release       Date:  2017-01-31       Impact factor: 9.776

5.  MT1-MMP-dependent remodeling of cardiac extracellular matrix structure and function following myocardial infarction.

Authors:  Gerald C Koenig; R Grant Rowe; Sharlene M Day; Farideh Sabeh; Jeffrey J Atkinson; Kenneth R Cooke; Stephen J Weiss
Journal:  Am J Pathol       Date:  2012-03-29       Impact factor: 4.307

6.  Decreased homodimerization and increased TIMP-1 complexation of uteroplacental and uterine arterial matrix metalloproteinase-9 during hypertension-in-pregnancy.

Authors:  Juanjuan Chen; Zongli Ren; Minglin Zhu; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2017-05-12       Impact factor: 5.858

7.  Proteolytic processing of membrane-type-1 matrix metalloproteinase is associated with gelatinase A activation at the cell surface.

Authors:  K Lehti; J Lohi; H Valtanen; J Keski-Oja
Journal:  Biochem J       Date:  1998-09-01       Impact factor: 3.857

8.  Co-cultures of human coronary smooth muscle cells and dimethyl sulfoxide-differentiated HL60 cells upregulate ProMMP9 activity and promote mobility-modulation by reactive oxygen species.

Authors:  Yohann Bernard; Chantal Melchior; Eric Tschirhart; Jean-Luc Bueb
Journal:  Inflammation       Date:  2008-10       Impact factor: 4.092

9.  Expression of MT-1 MMP, MMP2, MMP9 and TIMP2 mRNAs in ductal carcinoma in situ and invasive ductal carcinoma of the breast.

Authors:  Hee Jung Kim; Chan-il Park; Byeong Woo Park; Hy-de Lee; Woo Hee Jung
Journal:  Yonsei Med J       Date:  2006-06-30       Impact factor: 2.759

10.  Chordin-Like 1 Suppresses Bone Morphogenetic Protein 4-Induced Breast Cancer Cell Migration and Invasion.

Authors:  Chanèle Cyr-Depauw; Jason J Northey; Sébastien Tabariès; Matthew G Annis; Zhifeng Dong; Sean Cory; Michael Hallett; Jonathan P Rennhack; Eran R Andrechek; Peter M Siegel
Journal:  Mol Cell Biol       Date:  2016-05-02       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.